Lung Cancer Research Foundation Partners with AstraZeneca to Fund SCLC Research Initiatives

Call for Innovative Research in Small Cell Lung Cancer

In a collaborative effort to combat the challenges faced in treating Small Cell Lung Cancer (SCLC), the Lung Cancer Research Foundation (LCRF) and AstraZeneca have announced an exciting opportunity for researchers. This initiative focuses on advancing treatment strategies and enhancing outcomes for patients suffering from this aggressive cancer type.

The Research Awards Explained

LCRF is offering two prestigious research grants aimed at fostering groundbreaking solutions in SCLC treatment. The 2026 LCRF | AstraZeneca Research Award on Strategies Towards Improving the Treatment of Small Cell Lung Cancer features a total funding of $500,000 over three years, with the potential to significantly impact the care continuum and survivorship rates. Researchers are encouraged to propose innovative ideas that could lead to new therapeutic strategies and enhance the understanding of SCLC biology.

Additionally, the 2026 LCRF | AstraZeneca Research Award on Strategies Using Patient Advocacy to Improve Outcomes in Small Cell Lung Cancer introduces a $250,000 grant over two years. This award emphasizes the critical role of patient advocacy in shaping effective outcomes and aims to mobilize research efforts to improve both quality of life and overall cancer survivorship for patients.

The Urgency for Innovative Solutions

Historically, progress in the treatment of SCLC has lagged compared to non-small cell lung cancer (NSCLC), largely due to a limited understanding of the disease’s biological mechanisms. SCLC’s propensity for rapid growth and metastasis, combined with a high rate of treatment resistance, presents significant barriers. While first-line treatments often yield initial effectiveness through DNA-damaging chemotherapy, the effectiveness decreases dramatically over time, necessitating new therapeutic strategies.

Advocacy has historically played a pivotal role in addressing significant health concerns across various medical fields, including HIV/AIDS and breast cancer. Lung cancer, although it remains the leading cause of cancer-related deaths in the U.S., suffers from an acute lack of advocacy and research funding due to persistent stigmas surrounding smoking and lung cancer.

Objectives of the Research Awards

The two research awards presented by LCRF and AstraZeneca aim to change this narrative by focusing not only on advancing medical research but also engaging the patient community. Dr. Antoinette Wozniak, Chief Scientific Officer for LCRF, expressed excitement about inviting researchers to submit bold proposals that can address some of the most pressing challenges in SCLC treatment.

The awards will support work that is expected to yield significant insights into SCLC subtypes and therapeutic targets that previously were not considered viable. This includes the potential integration of newer therapies and the critical incorporation of patient-driven advocacy efforts, which can drive public awareness and impact policy decisions.

The Application Process

Researchers interested in applying for these grants must submit a Letter of Intent by July 15, 2026. Following the initial review, selected candidates will be invited to present full proposals undergoing rigorous evaluation by LCRF's Scientific Advisory Board. Such a structured approach ensures that the research directed by these grants aligns with the immediate needs of the SCLC patient community and leads to feasible, actionable outcomes.

Bridging Gaps in Cancer Care

AstraZeneca's US Medical Head for Lung Cancer, Nabil Chehab, highlighted the profound need for deeper insights into SCLC biology to foster precise therapies. The anticipation surrounding this partnership with LCRF aims to illuminate new areas for exploration and ultimately enhance various aspects of patient treatment.

Dr. Misty Dawn Shields from Indiana University echoed these sentiments, emphasizing how crucial the timing is for such initiatives. As new science surrounding SCLC continues to develop, these research grants may serve as a launchpad for treatments that genuinely improve patient outcomes.

In conclusion, the LCRF and AstraZeneca partnership stands as a beacon of hope for the SCLC community, promising future advances and improved care through innovative research. For researchers across the globe looking to make a mark in the oncology field, this is an opportunity to contribute to transformative change in lung cancer treatment and advocacy.